ERBB2 is a transmembrane receptor tyrosine kinase that functions as a critical oncogenic driver in multiple cancer types. At the cell surface, ERBB2 activates phosphatidylinositol 3-kinase/protein kinase B and Erk signaling pathways in response to growth factor stimulation, promoting cell proliferation and survival 1. The receptor can form heteromeric complexes with other ErbB family members, including a trastuzumab-resistant p95-ErbB2 splice variant that cooperatively regulates Hippo signaling and SOX2 gene expression to enhance anchorage-independent proliferation 1. Beyond cytoplasmic signaling, ERBB2 translocates to the nucleus where it functions in transcriptional regulation, associating with the PTGS2/COX-2 promoter and regulating CDKN1A expression through STAT3 and SRC [UniProt]. ERBB2 amplification occurs in approximately 6.1% of gastric cancers and shows positive correlation with mRNA expression and proliferative markers 2. Clinically, ERBB2 overexpression is targeted by trastuzumab (Herceptin) for breast cancer therapy, though resistance mechanisms and cardiotoxicity remain clinical challenges 3. Recent studies demonstrate that constitutively active ERBB2 potently stimulates cardiomyocyte proliferation through Erk signaling, suggesting potential therapeutic applications for cardiac regeneration 4. Environmental exposures, such as lead, may influence ERBB2 expression levels in healthy populations 5.